✦ LIBER ✦

Ibritumomab tiuxetan (Zevalin) in the conditioning regimen for autologous and reduced-intensity allogeneic stem-cell transplantation (SCT) in patients with chemo-refractory non-hodgkin’s lymphoma

✍ Scribed by A. Shimoni; T. Zwass; Y. Oksman; I. Hardan; N. Shem-Tov; R. Yerushalmi; A. Avigdor; I. Ben-Bassat; A. Nagler

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Ibritumomab tiuxetan (Zevalin) combined

✍ Shimoni, A; Zwas, S T; Oksman, Y; Hardan, I; Shem-Tov, N; Rand, A; Yerushalmi, R 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 155 KB

Yttrium-90–ibritumomab tiuxetan (Zevalin

✍ Avichai Shimoni; S. Tzila Zwas; Yakov Oksman; Izhar Hardan; Noga Shem-Tov; Ronit 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 186 KB

Reduced-Intensity Allogeneic Versus Auto

✍ C.H. Gutierrez-Aguirre; O.G. Cantu-Rodriguez; O. Gonzalez-Llano; J.C. Jaime-Pere 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 64 KB

Allogeneic stem cell transplantation (SC

✍ L. Raida; E. Faber; T. Papajik; K. Indrak; J. Zapletalova; A. Vitek; V. Koza 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 53 KB

A randomized study comparing yttrium-90

✍ Avichai Shimoni; Irit Avivi; Jacob M. Rowe; Moshe Yeshurun; Itai Levi; Reuven Or 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 278 KB

Reduced intensity conditioning and allog

✍ Wulf, G G; Hasenkamp, J; Jung, W; Chapuy, B; Truemper, L; Glass, B 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 86 KB